Press Release
January 23rd, 2023

CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal

Press Release
April 12th, 2022

CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers

Press Release
February 10th, 2022

CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development

Press Release
September 30th, 2021

Cytoreason and Summit Pharmaceuticals International forge commercial alliance to bring CytoReason’s machine learning model of the immune system for drug discovery & development to Japanese drug makers

Press Release
June 17th, 2021

CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms

Press Release
May 19th, 2021

CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology

Bring your data to life